BioBiz Buzz
by https://biobizbuzz.com/
29. From overlooked science to investable biotech: The 2026…
About this podcast
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Episodes
The newest 20 of 29 episodes
- 29. From overlooked science to investable biotech: The 2026 Strüngmann Award. · 33 min · Season 3 Episode 1What transforms a promising scientific opportunity into a viable biotechnology company? In this episode of BioBiz Buzz, Mike Ward speaks with Dr Jonathan Talbot, CEO of Melodia…
- 28. Reawakening Wnt Biology: Neuvasq’s Approach to Restoring Retinal Vascular Integrity · 28 min · Season 2 Episode 9In this episode of BioBiz Buzz, your host Mike Ward explores a critical, but often underappreciated, driver of vision loss in retinal diseases; the breakdown of the blood–retina…
- 27. Microbiome Medicines at Scale: MRM Health’s Mission to Redefine Immune-Mediated Disease · 32 min · Season 2 Episode 7In this episode of BioBiz Buzz, Mike Ward talks to Dr Sam Possemiers, founder and CEO of Belgium-based MRM Health, about what it really takes to turn the human gut microbiome…
- 26. Induced Proximity 2.0: How Proxygen Is Rewiring Targeted Protein Degradation for the Clinic · 31 min · Season 2 Episode 8Targeted protein degradation has moved from elegant academic concept to one of the most closely watched frontiers in oncology, promising to drug the 80% of disease‑driving…
- 25. Europe Doesn’t Need Boston Anymore: Inside Gilead’s $5B Tubulis Bet · 18 min · Season 2 Episode 6For years, the narrative was simple: if you wanted a multibillion-dollar biotech outcome, you built in Boston or the Bay Area. Gilead’s up to $5 billion acquisition of…
- 24. AL-S Pharma prepping a phase 3 trial of AP-101 in ALS · 27 min · Season 2 Episode 5Progress in developing safe and effective therapies for amyotrophic lateral sclerosis (ALS) has been painfully slow. It is caused by the death of motor neurons in the central…
- 23. Thalia’s Big Bet on Gene Silencing: Once‑Yearly RNA to Tackle Hidden Cardiac Risk · 24 min · Season 2 Episode 4What if an annual self-injection could silence your hidden cardiac risk instead of just lowering your LDL? In this episode of BioBiz Buzz, Mike Ward sits down with David Solomon…
- 22. Unlocking the Undruggable: Quantro Therapeutics’ Mission to Transform Cancer Treatment · 38 min · Season 2 Episode 3For more than three decades, transcription factors have been the great white whale of oncology drug discovery; tantalising, genetically validated, mechanistically central, and…
- 21. Targeting What Others Miss: How HaemaLogiX Is Tackling Multiple Myeloma's Toughest Challenges · 30 min · Season 2 Episode 2Multiple myeloma remains the second-largest blood cancer globally with no cure, and despite recent breakthroughs in CAR-T and antibody therapies, patients continue to relapse…
- 20. Redefining HIV Treatment and Prevention: Gilead’s Next Chapter · 34 min · Season 2 Episode 1In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Jared Baeten, Senior Vice President for Clinical Development and Head of the Virology Therapeutic Area at…
- 19. From Genesis to Revelations: Winners & Losers in Pharma’s Most Volatile Year · 25 min · Season 1 Episode 192025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode…
- 18. Putting solid tumours under the T-knife: how a next-gen TCR aims to crack them · 23 min · Season 1 Episode 18Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies. The…
- 17. Democratizing Drug Discovery: How Lilly ExploR&D Is Changing the Biotech Playbook · 28 min · Season 1 Episode 17The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D…
- 16. The Smart Money Talks: Inside Sofinnova's Bold €650M Fundraise · 25 min · Season 1 Episode 16In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has…
- 15. Targeting Misfolded SOD1 in ALS: A First-in-Class Antibody Shows Promise · 32 min · Season 1 Episode 15This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting…
- 14. The NanoPortal platform: Vivani Medical is reimagining how GLP-1s are delivered. · 17 min · Season 1 Episode 14GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a…
- 13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment · 32 min · Season 1 Episode 13Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025…
- 12. Revolution technology set to transform breast cancer diagnosis and treatment. · 20 min · Season 1 Episode 12Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according…
- 11. A technological breakthrough in the diagnosis of skin cancer · 26 min · Season 1 Episode 11AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates…
- 10. How Bioxodes is using tick saliva to create an ICH stroke treatment breakthrough · 26 min · Season 1 Episode 10In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc…







